Malta - English - Medicines Authority

thrive pharma ltd 12 nikolay haytov str., fl.5, office 19, sofia, 1113 , bulgaria - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - English - Medicines Authority

thrive pharma ltd 12 nikolay haytov str., fl.5, office 19, sofia, 1113 , bulgaria - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tobramycin, quantity: 60 mg/ml - inhalation, conventional - excipient ingredients: water for injections; sodium hydroxide; sulfuric acid; sodium chloride - tobi is indicated for the management of cystic fibrosis patients with p.aeruginosa infections. safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev,<25% or >75% predicted, or patients colonised with burkolderia cepacia (see clinical trials).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 97.2mg (4mmol)) chewable tablets sugar free (colonis pharma ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 97.2mg (4mmol)) chewable tablets sugar free (colonis pharma ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 97.2mg (4mmol)) chewable tablets (colonis pharma ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - fluconazole -

European Union - English - myHealthbox

forest laboratories uk ltd - colistimethate sodium - inhalation powder, hard capsule - each capsule contains 1662500iu (approximately equal to 125mg) of colistimethate sodium - cystic fibrosis - antibacterials for systemic use - colobreathe is indicated for the management of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older